Climb Bio (CLYM) Invested Capital (2020 - 2026)
Climb Bio filings provide 7 years of Invested Capital readings, the most recent being $148.1 million for Q1 2026.
- Quarterly Invested Capital fell 23.42% to $148.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $148.1 million through Mar 2026, down 23.42% year-over-year, with the annual reading at $160.5 million for FY2025, 24.26% down from the prior year.
- Invested Capital hit $148.1 million in Q1 2026 for Climb Bio, down from $160.5 million in the prior quarter.
- Across five years, Invested Capital topped out at $222.3 million in Q2 2024 and bottomed at $106.4 million in Q1 2024.
- Average Invested Capital over 5 years is $154.8 million, with a median of $148.1 million recorded in 2026.
- The largest annual shift saw Invested Capital surged 459.27% in 2022 before it decreased 24.68% in 2023.
- Climb Bio's Invested Capital stood at $128.7 million in 2022, then decreased by 16.41% to $107.6 million in 2023, then soared by 96.92% to $211.9 million in 2024, then fell by 24.26% to $160.5 million in 2025, then decreased by 7.72% to $148.1 million in 2026.
- Per Business Quant, the three most recent readings for CLYM's Invested Capital are $148.1 million (Q1 2026), $160.5 million (Q4 2025), and $177.0 million (Q3 2025).